Silke Aigner

1.5k total citations
18 papers, 1.1k citations indexed

About

Silke Aigner is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Allergy and Immunology. According to data from OpenAlex, Silke Aigner has authored 18 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Radiology, Nuclear Medicine and Imaging, 6 papers in Immunology and Allergy and 6 papers in Immunology. Recurrent topics in Silke Aigner's work include Cell Adhesion Molecules Research (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and T-cell and B-cell Immunology (4 papers). Silke Aigner is often cited by papers focused on Cell Adhesion Molecules Research (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and T-cell and B-cell Immunology (4 papers). Silke Aigner collaborates with scholars based in Germany, United States and Hungary. Silke Aigner's co-authors include Peter Altevogt, Marei Sammar, Marcus Hubbe, Dietmar Vestweber, Zev Sthoeger, Ali Hafezi‐Moghadam, Jan Friederichs, Michael B. Lawrence, Carroll L. Ramos and Klaus Ley and has published in prestigious journals such as The Journal of Cell Biology, Blood and The FASEB Journal.

In The Last Decade

Silke Aigner

17 papers receiving 1.0k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Silke Aigner 469 429 316 286 166 18 1.1k
Christie J. Avraamides 782 1.7× 572 1.3× 400 1.3× 376 1.3× 161 1.0× 6 1.5k
Helena Kiefel 605 1.3× 341 0.8× 120 0.4× 253 0.9× 134 0.8× 23 1.2k
Philippe Pujuguet 542 1.2× 446 1.0× 283 0.9× 112 0.4× 156 0.9× 22 1.1k
Chrystelle Lamagna 439 0.9× 270 0.6× 221 0.7× 605 2.1× 85 0.5× 18 1.2k
Kristin A. Atkins 465 1.0× 509 1.2× 154 0.5× 187 0.7× 98 0.6× 10 1.1k
Shahinoor Begum 404 0.9× 409 1.0× 104 0.3× 158 0.6× 86 0.5× 13 988
W J Rettig 468 1.0× 360 0.8× 150 0.5× 157 0.5× 93 0.6× 19 962
Gabriel J. Villares 666 1.4× 330 0.8× 124 0.4× 241 0.8× 97 0.6× 19 1.2k
Charlotte Rorsman 668 1.4× 182 0.4× 144 0.5× 206 0.7× 112 0.7× 15 1.1k
Ine M. H. A. Cornelissen 377 0.8× 248 0.6× 279 0.9× 140 0.5× 137 0.8× 19 765

Countries citing papers authored by Silke Aigner

Since Specialization
Citations

This map shows the geographic impact of Silke Aigner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silke Aigner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silke Aigner more than expected).

Fields of papers citing papers by Silke Aigner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silke Aigner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silke Aigner. The network helps show where Silke Aigner may publish in the future.

Co-authorship network of co-authors of Silke Aigner

This figure shows the co-authorship network connecting the top 25 collaborators of Silke Aigner. A scholar is included among the top collaborators of Silke Aigner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silke Aigner. Silke Aigner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
2.
Kriván, Gergely, Michael Borte, Pere Soler‐Palacín, et al.. (2022). BT595, a 10% Human Normal Immunoglobulin, for Replacement Therapy of Primary Immunodeficiency Disease: Results of a Subcohort Analysis in Children. Journal of Clinical Immunology. 43(3). 557–567. 2 indexed citations
3.
Demeter, Judit, et al.. (2022). Efficacy and safety of BT595 (10% human intravenous immunoglobulin) in adult patients with chronic immune thrombocytopenia. Transfusion Medicine. 33(2). 165–173. 4 indexed citations
4.
Kriván, Gergely, Michael Borte, James B. Harris, et al.. (2022). Efficacy, safety and pharmacokinetics of a new 10% normal human immunoglobulin for intravenous infusion, BT595, in children and adults with primary immunodeficiency disease. Vox Sanguinis. 117(10). 1153–1162. 3 indexed citations
5.
Vollenhoven, Ronald van, Edward Keystone, Vibeke Strand, et al.. (2018). Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial. Annals of the Rheumatic Diseases. 77(4). 495–499. 9 indexed citations
6.
König, Martin, Faı̈za Rharbaoui, Silke Aigner, Benjamin Dälken, & Jörg Schüttrumpf. (2016). Tregalizumab – A Monoclonal Antibody to Target Regulatory T Cells. Frontiers in Immunology. 7. 32 indexed citations
7.
Erb, Michael A., et al.. (2015). Radiation Exposure and Contrast Volume Differ between Transapical and Transfemoral Aortic Valve Implantation with the Edwards SAPIEN Aortic Valve. The Thoracic and Cardiovascular Surgeon. 63(6). 479–486. 3 indexed citations
8.
Aigner, Silke, Olga Ab, Kathleen R. Whiteman, et al.. (2010). BT062, a CD138-Specific Immunoconjugate, Demonstrates Superior In Vivo Anti-Myeloma Efficacy In Combination with Lenalidomide or Bortezomib. Blood. 116(21). 3008–3008. 5 indexed citations
9.
Trollmo, Christina, Christian Becker, Helmut Jonuleit, et al.. (2010). (1125) - Selective Activation of Naturally Occurring Regulatory T Cells (Tregs) by the Monoclonal Antibody (mAb) BT-061. Markers of Clinical Activity and Early Phase II Results in Patients with Rheumatoid Arthritis (RA). 4 indexed citations
10.
Zuber, Chantal, Benjamin Dälken, Silke Aigner, et al.. (2010). 226 High in vivo anti-tumor activity of the immunoconjugate BT-062 against CD138 positive solid tumors. European Journal of Cancer Supplements. 8(7). 74–74. 1 indexed citations
11.
Alferink, Judith, Silke Aigner, Roland Reibke, Günter J. Hämmerling, & Bernd Arnold. (1999). Peripheral T‐cell tolerance: the contribution of permissive T‐cell migration into parenchymal tissues of the neonate. Immunological Reviews. 169(1). 255–261. 24 indexed citations
12.
Aigner, Silke, Carroll L. Ramos, Ali Hafezi‐Moghadam, et al.. (1998). CD24 mediates rolling of breast carcinoma cells on P‐selectin. The FASEB Journal. 12(12). 1241–1251. 235 indexed citations
13.
Sammar, Marei, Silke Aigner, & Peter Altevogt. (1997). Heat-stable antigen (mouse CD24) in the brain: dual but distinct interaction with P-selectin and L1. Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology. 1337(2). 287–294. 49 indexed citations
14.
Aigner, Silke, Zev Sthoeger, Mina Fogel, et al.. (1997). CD24, a Mucin-Type Glycoprotein, Is a Ligand for P-Selectin on Human Tumor Cells. Blood. 89(9). 3385–3395. 271 indexed citations
15.
Aigner, Silke, et al.. (1996). L1 adhesion molecule on human lymphocytes and monocytes: expression and involvement in binding to αvβ3 integrin. European Journal of Immunology. 26(10). 2508–2516. 98 indexed citations
16.
Aigner, Silke, Marcus Hubbe, Marei Sammar, et al.. (1995). Heat stable antigen (mouse CD24) supports myeloid cell binding to endothelial and platelet P-selectin. International Immunology. 7(10). 1557–1565. 91 indexed citations
17.
Aigner, Silke, et al.. (1995). The L1 adhesion molecule is a cellular ligand for VLA-5.. The Journal of Cell Biology. 131(6). 1881–1891. 127 indexed citations
18.
Sammar, Marei, Silke Aigner, Marcus Hubbe, et al.. (1994). Heat-stable antigen (CD24) as ligand for mouse P-selectin. International Immunology. 6(7). 1027–1036. 100 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026